Literature DB >> 16570182

The enigmatic nature of apocrine breast lesions.

P Zagorianakou1, N Zagorianakou, D Stefanou, G Makrydimas, N J Agnantis.   

Abstract

Epithelial cells of fetal breast glandular structures, at the third trimester of pregnancy (28 weeks), produce GCDFP-15, in the absence of specific apocrine morphology. Apocrine epithelium of the breast may be a normal process of differentiation rather than a result of metaplasia, and it has been demonstrated that it is estrogen-receptor, progesterone-receptor and bcl-2 negative, but androgen-receptor (AR) positive. The significance of AR expression in apocrine epithelium is uncertain. Apocrine epithelium is seen in a wide spectrum of breast entities, ranging from benign lesions to invasive carcinoma. Breast cancer accounts 32% of all cancer cases among women and is the most common type of cancer in women. Little is known about breast carcinogenesis. Widely, it is accepted that breast cancer, like most other type of cancer, is being developed through the accumulation of genetic aberrations. Apocrine epithelium may reflect instability of the breast epithelium, creating an environment favouring further oncogenic alterations. In the last decade, several lines of evidence support the idea that some breast benign epithelial apocrine lesions are clonal lesions and may be considered as truly pre-malignant or precursors of breast carcinoma. Apocrine changes in many cases do not present any diagnostic difficulty; on the other hand, apocrine proliferations with cytologic atypia can be particularly difficult and challenging. The purpose of this study is to collect and highlight the areas of consensus in the literature as well as the controversial areas concerning the apocrine epithelium of the breast.

Entities:  

Mesh:

Year:  2006        PMID: 16570182     DOI: 10.1007/s00428-005-0095-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  77 in total

1.  Apocrine metaplasia in cystic hyperplastic mastopathy. Histochemical and ultrastructural observations.

Authors:  A Ahmed
Journal:  J Pathol       Date:  1975-04       Impact factor: 7.996

Review 2.  Review of GCDFP-15. An apocrine marker protein.

Authors:  D E Haagensen; W G Dilley; G Mazoujian; S A Wells
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

3.  The ultrastructure of apocrine cells in intracystic papilloma and fibrocystic disease of the breast.

Authors:  W J Pier; J C Garancis; J F Kuzma
Journal:  Arch Pathol       Date:  1970-05

Review 4.  Human breast development.

Authors:  B A Howard; B A Gusterson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-04       Impact factor: 2.673

5.  Levels of eighteen non-conjugated and conjugated steroids in human breast cyst fluid: relationships with cyst type.

Authors:  A Bélanger; S Caron; F Labrie; C Naldoni; L Dogliotti; A Angeli
Journal:  Eur J Cancer       Date:  1990-03       Impact factor: 9.162

6.  Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases.

Authors:  F A Tavassoli; H J Norris
Journal:  Mod Pathol       Date:  1994-10       Impact factor: 7.842

7.  Lobular endocrine neoplasia in fibroadenoma of the breast.

Authors:  V Eusebi; J G Azzopardi
Journal:  Histopathology       Date:  1980-07       Impact factor: 5.087

8.  Epidermal growth factor in breast cyst fluid: relationship with intracystic cation and androgen conjugate content.

Authors:  F Boccardo; G Valenti; S Zanardi; G Cerruti; T Fassio; P Bruzzi; V De Franchis; A Barreca; P Del Monte; F Minuto
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

Review 9.  Needle aspiration biopsy: past, present, and future.

Authors:  W J Frable
Journal:  Hum Pathol       Date:  1989-06       Impact factor: 3.466

10.  Is there an increased risk of breast cancer in women who have had a breast cyst aspirated?

Authors:  N J Bundred; R R West; J O Dowd; R E Mansel; L E Hughes
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more
  6 in total

1.  History of benign breast disease and risk of breast cancer among women in China: a case-control study.

Authors:  Tsogzolmaa Dorjgochoo; Sandra L Deming; Yu-Tang Gao; Wei Lu; Ying Zheng; Zhixian Ruan; Wei Zheng; Xiao Ou Shu
Journal:  Cancer Causes Control       Date:  2008-03-18       Impact factor: 2.506

2.  A functional and regulatory network associated with PIP expression in human breast cancer.

Authors:  Marie-Anne Debily; Sandrine El Marhomy; Virginie Boulanger; Eric Eveno; Régine Mariage-Samson; Alessandra Camarca; Charles Auffray; Dominique Piatier-Tonneau; Sandrine Imbeaud
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

3.  Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

Authors:  Maria Vittoria Dieci; Enrico Orvieto; Massimo Dominici; PierFranco Conte; Valentina Guarneri
Journal:  Oncologist       Date:  2014-06-26

4.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

5.  Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast.

Authors:  Trine Tramm; Jee-Yeon Kim; Sebastian Leibl; Farid Moinfar; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-06-10       Impact factor: 4.064

6.  Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Authors:  Jacqueline Lehmann-Che; Anne-Sophie Hamy; Raphaël Porcher; Marc Barritault; Fatiha Bouhidel; Hanadi Habuellelah; Solenne Leman-Detours; Anne de Roquancourt; Laurence Cahen-Doidy; Edwige Bourstyn; Patricia de Cremoux; Cedric de Bazelaire; Marcela Albiter; Sylvie Giacchetti; Caroline Cuvier; Anne Janin; Marc Espié; Hugues de Thé; Philippe Bertheau
Journal:  Breast Cancer Res       Date:  2013-05-11       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.